Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …
Treatment optimization in early triple negative breast cancer
Introduction The treatment of early-stage triple-negative breast cancer (TNBC) has radically
changed in recent years. Response to neoadjuvant treatment has provided prognostic …
changed in recent years. Response to neoadjuvant treatment has provided prognostic …
Which patients do we need to test for BRCA1/2 mutation? Feasibility of adjuvant olaparib treatment in early breast cancer–real-world data from two large German …
Simple Summary Targeted therapies are increasingly used in patients with early breast
cancer and a high clinical risk of relapse. Patients with clinical high-risk HER2-negative …
cancer and a high clinical risk of relapse. Patients with clinical high-risk HER2-negative …
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A …
Background Breast cancer patients with residual disease after neoadjuvant therapy have
increased risk of recurrence. Novel therapies to decrease this risk are urgently needed …
increased risk of recurrence. Novel therapies to decrease this risk are urgently needed …
A Comprehensive Review on the State of the Art of Breast Cancers in Italy
D Iacopetta, J Ceramella, A Catalano… - Current Medicinal …, 2024 - benthamdirect.com
Breast cancer (BC) currently represents one of the most prevalent cancers among women
worldwide and the leading cause of cancer death among women, also negatively affecting …
worldwide and the leading cause of cancer death among women, also negatively affecting …